Tumor News and Research

RSS

A model of melanoma generates hope for the use of targeted therapies

Researchers have developed a new mouse model that allows them to replicate normal pigment cells at the earliest stages of conversion to malignant skin cancer in humans.

12 Mar 2009

New investigational therapy for the treatment of bladder cancer

A team of researchers, led by Columbia University Medical Center faculty, has identified a new investigational therapy for the treatment of bladder cancer.

12 Mar 2009

Multiple route bone marrow stem cell injections show promise to treat spinal cord injury

Researchers from DaVinci Biosciences, Costa Mesa, California, in collaboration with Hospital Luis Vernaza in Ecuador, have determined that injecting a patient's own bone marrow-derived stem cells (autologous BMCs) directly into the spinal column using multiple routes can be an effective treatment for spinal cord injury (SCI) that returns some quality of life for SCI patients without serious adverse events.

12 Mar 2009

Biothera receives approval to launch two lung cancer trials

German regulatory authorities have granted approval to Biothera to conduct two open label, multicenter, randomized Phase II clinical trials studying Imprime PGGÂ® administered in combination with monoclonal antibodies and chemotherapy in patients with non-small cell lung cancer (NSCLC), the company announced today.

12 Mar 2009

New measure for the malignancy of melanoma

Every tumor, starting from a size of a few millimeters, depends on a supply of nutrients and oxygen.

12 Mar 2009

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Genentech, Inc. and Biogen Idec has announced that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks.

11 Mar 2009

Discovery of cellular pathway that prevents cancer response to diet restriction

Whitehead Institute researchers have pinpointed a cellular pathway that determines whether cancerous tumors respond to dietary restriction during their development.

11 Mar 2009

MRI and CT used to map intelligence in the brain

Neuroscientists at the California Institute of Technology (Caltech) have conducted the most comprehensive brain mapping to date of the cognitive abilities measured by the Wechsler Adult Intelligence Scale (WAIS), the most widely used intelligence test in the world.

11 Mar 2009

Cell pathway on overdrive prevents cancer response to dietary restriction

Whitehead Institute researchers have pinpointed a cellular pathway that determines whether cancerous tumors respond to dietary restriction during their development.

11 Mar 2009

Twin nanoparticle targets then zaps breast cancer cells

Breast cancer patients face many horrors, including those that arise when fighting the cancer itself.

11 Mar 2009

Immune-based therapy approved in Europe for pediatric cancer patients

The European Commission, which oversees legislation and regulation for the European Union, has approved a therapy for pediatric patients with non-metastatic, resectable osteosarcoma, a type of bone cancer.

11 Mar 2009

New staging technique might save bladders in some bladder cancer patients

Pathologists have reported encouraging results from a new technique to increase the accuracy of staging bladder cancer tumors that could reduce the need to remove bladders from some patients.

10 Mar 2009

Metastatic bone disease patients can walk in Lazarus' footsteps

Osteoplasty - a highly effective minimally invasive procedure to treat the painful effects of metastatic bone disease by injecting bone cement to support weakened bones - provides immediate and substantial pain relief, often presenting individuals who are suffering terribly with the miraculous so-called "Lazarus effect," according to researchers at the Society of Interventional Radiology's 34th Annual Scientific Meeting.

10 Mar 2009

Male lumpectomy - first line treatment for prostate cancer

The so-called "male lumpectomy" - a minimally invasive interventional radiology treatment for prostate cancer - is as effective as surgery in destroying diseased tumors and can be considered a first-line treatment for patients of all risk levels and particularly those who have failed radiation, according to studies released at the Society of Interventional Radiology's 34th Annual Scientific Meeting.

10 Mar 2009

Freezing kidney cancer - interventional cryoablation

Freezing kidney tumors - using a safe minimally invasive interventional radiology treatment that kills the cancer 100 percent effectively without surgery - should be the gold standard or first treatment option for all individuals with tumors that are 4 centimeters in size or smaller.

10 Mar 2009

Azaya Therapeutics selected for Nanotechnology Characterization Lab by National Cancer Institute

Azaya Therapeutics, Inc. has announced that it has been selected by the National Cancer Institute (NCI) for a research collaboration to study Azaya's lead cancer therapy, ATI - 1123.

10 Mar 2009

New NYP course: Surgical approaches to the skull base

The skull base is not just a simple platform for the brain but an anatomically intricate area with an array of connections necessary to the body's essential functions.

8 Mar 2009

Serious flaws in study on vitamin C treatment in cancer

Serious flaws in a recent study, which concluded that high doses of vitamin C reduce the effectiveness of chemotherapeutic drugs in the treatment of cancer, are revealed in the current issue of Alternative and Complementary Therapies.

5 Mar 2009

Genome scanning system used to uncover suspect mutations in normal inherited genes

Scientists at the Sol Goldman Pancreatic Cancer Research Center at the Johns Hopkins Kimmel Cancer Center have used "personalized genome" sequencing on an individual with a hereditary form of pancreatic cancer to locate a mutation in a gene called PALB2 that is responsible for initiating the disease.

5 Mar 2009

Number of cardiovascular risk factors could determine safety of IVIg treatment

New research out of Wake Forest University School of Medicine identifies the presence of cardiovascular risk factors as an indicator of how likely it is that elderly, hospitalized patients who receive intravenous immunoglobulin (IVIg) treatment will have a stroke or heart attack.

5 Mar 2009